CHAPTER 1. INTRODUCTION
1.1. Market Definition
1.2. Executive Summary
1.3. The Scope of the Study
CHAPTER 2. RESEARCH METHODOLOGY
2.1. Secondary Research
2.2. Primary Research
2.3. Analytic Tools and Model
2.4. Economic Indicator
2.4.1 Base Year, Base Currency, Forecasting Period
2.5. Expert Validation
2.6. Study Timeline
CHAPTER 3. MARKET ANALYSIS
3.1. Industry Value Chain Analysis
3.2. Porter's Five Force Analysis
3.2.1. Bargaining Power of Buyers
3.2.2. Bargaining Power of Suppliers
3.2.3. Threats of Substitutes
3.2.4. Threats of New Entrants
3.2.5. Degree of Competition
3.3. PESTLE Analysis
3.3.1. Political
3.3.2. Economical
3.3.3. Social
3.3.4. Technological
3.3.5. Legal
3.3.6. Environmental
3.4. SWOT Analysis
3.4.1. Strengths
3.4.2. Weakness
3.4.3. Opportunities
3.4.4. Threats
3.5. Y-O-Y Analysis
CHAPTER 4. MARKET DYNAMICS
4.1. Market Drivers
4.1.1. Favourable funding scenario for cancer research
4.1.2. Increasing R&D activities in biopharmaceutical companies
4.1.3. A significant increase in venture capital investments
4.1.4. Increasing prevalence of chronic diseases
4.2. Market Restraints & Challenges
4.2.1. Implementation of excise duty by the U.S government
4.2.2. Quality concerns over research antibodies
4.3. Market Opportunities
4.3.1. Growth opportunities in emerging markets
4.3.2. Emerging economies
CHAPTER 5. GLOBAL CELL DISSOCIATION MARKET – BY PRODUCT
5.1. Introduction
5.2. Enzymatic dissociation products
5.2.1. Hyaluronidase
5.2.2. Trypsin
5.2.3. Papain
5.2.4. Elastase
5.2.5. DNase
5.2.6. Collagenase
5.2.7. Other Enzymes
5.3. Instruments & Accessories
5.4. Non-Enzymatic dissociation products
CHAPTER 6. GLOBAL CELL DISSOCIATION MARKET - BY TYPE
6.1. Introduction
6.2. Cell detachment
6.3. Tissue dissociation
CHAPTER 7. GLOBAL CELL DISSOCIATION MARKET - BY TISSUE
7.1. Introduction
7.2. Epithelial tissue
7.3. Connective tissue
7.4. Other tissue
CHAPTER 8. GLOBAL CELL DISSOCIATION MARKET - BY END USER
8.1 Introduction
8.2 Research & academic institutes
8.3 Pharmaceutical & biotechnology companies
8.4 Other end users
CHAPTER 9. GLOBAL CELL DISSOCIATION MARKET - BY GEOGRAPHY
9.1. Introduction
9.2. North America
9.2.1. U.S.
9.2.2. Canada
9.2.3. Mexico
9.2.4. Costa Rica
9.3. South America
9.3.1. Brazil
9.3.2. Argentina
9.3.3. Chile
9.3.4. Columbia
9.3.5. Others
9.4. Europe
9.4.1. U.K.
9.4.2. Germany
9.4.3. France
9.4.4. Italy
9.4.5. Spain
9.4.6. Russia
9.4.7. Netherlands
9.4.8. Switzerland
9.4.9. Poland
9.4.10. Others
9.5. APAC
9.5.1. China
9.5.2. Japan
9.5.3. India
9.5.4. South Korea
9.5.5. Australia & New Zealand
9.5.6. Malaysia
9.5.7. Singapore
9.5.8. Others
9.6. Middle East & Africa
9.6.1. UAE
9.6.2. Saudi Arabia
9.6.3. Iran
9.6.4. Iraq
9.6.5. Qatar
9.6.6. South Africa
9.6.7. Algeria
9.6.8. Morocco
9.6.9. Nigeria
9.6.10. Egypt
9.6.11. Others
CHAPTER 10. GLOBAL CELL DISSOCIATION MARKET - COMPANY PROFILES
10.1. American Type Culture Collection.
10.2. Becton Dickinson & Company
10.3. Hoffmann-La Roche Ltd.
10.4. GE Healthcare.
10.5. Himedia Laboratories.
10.6. Merck KGaA.
10.7. Miltenyi Biotec.
10.8. Pan-Biotech.
10.9. Stem cell Technologies.
10.10. Thermo Fischer Scientific Inc.
10.11. STEMCELL Technologies, Inc.
10.12. Cyagen Biosciences, Inc.
10.13. Promo Cell GmbH.
10.14. Euro Clone S.p.A.
10.15. Irvine Scientific Sales Company, Inc.
CHAPTER 11. GLOBAL CELL DISSOCIATION MARKET - COMPETITIVE
LANDSCAPE
11.1. Market Share Analysis
11.2. Strategies adopted by top companies
11.3. Mergers, Acquisitions, Collaborations & Agreements
CHAPTER 12. MARKET INSIGHTS
12.1. Industry Experts Insights
12.2. Analysts Opinions
12.3. Investment Opportunities
CHAPTER 13. APPENDIX
13.1. List of Tables
13.2. List of Figures
